

## The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders

Gabor S. Ungvari<sup>1,2</sup>, Stanley N. Caroff<sup>3</sup>, and Jozsef Gerevich<sup>4</sup>

<sup>2</sup>Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China; <sup>3</sup>Department of Psychiatry, Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, PA; <sup>4</sup>Faculty of Orthopedagogics, Eotvos Lorand University, Budapest, Hungary

To provide a rational basis for reconceptualizing catatonia in *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition), we briefly review historical sources, the psychopathology of catatonia, and the relevance of catatonic schizophrenia in contemporary practice and research. In contrast to Kahlbaum, Kraepelin and others (Jaspers, Kleist, and Schneider) recognized the prevalence of motor symptoms in diverse psychiatric disorders but concluded that the unique pattern and persistence of certain psychomotor phenomena defined a “catatonic” subtype of schizophrenia, based on intensive long-term studies. The enduring controversy and confusion that ensued underscores the fact that the main problem with catatonia is not just its place in *Diagnostic and Statistical Manual of Mental Disorders* but rather its lack of conceptual clarity. There still are no accepted principles on what makes a symptom catatonic and no consensus on which signs and symptoms constitute a catatonic syndrome. The resulting heterogeneity is reflected in treatment studies that show that stuporous catatonia in any acute disorder responds to benzodiazepines or electroconvulsive therapy, whereas catatonia in the context of chronic schizophrenia is phenomenologically different and less responsive to either modality. Although psychomotor phenomena are an intrinsic feature of acute and especially chronic schizophrenia, they are insufficiently recognized in practice and research but may have significant implications for treatment outcome and neurobiological studies. While devising a separate category of catatonia as a non-specific syndrome has heuristic value, it may be equally if not more important to re-examine the psychopathological basis for defining psychomotor symptoms as catatonic and to re-establish psychomotor phenomena as a fundamental

symptom dimension or criterion for both psychotic and mood disorders.

*Key words:* catatonia/schizophrenia/classification/psychopathology

### Introduction

The revision of *Diagnostic and Statistical Manual of Mental Disorders* (DSM) offers a critical opportunity to address the nosological status of catatonia. In past iterations, “catatonic” symptoms have been vaguely defined, incomplete, and included as a subtype or modifier for schizophrenia, mood disorders, or medical conditions, without a clear theoretical or evidentiary basis. This shortcoming of DSM reflects the neglect of classical literature and descriptive psychopathology in contemporary training, practice, and research.

To provide a rational basis for the nosological status of catatonia in *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition) (DSM-V), we briefly review historical sources, the complexities of the psychopathology of catatonia, and the validity of catatonic schizophrenia. Available evidence indicates that catatonic symptoms are described in association with numerous brain disorders, supporting the conceptualization of catatonia as a nonspecific syndrome as reviewed by Fink et al<sup>1</sup> in this issue. While we agree that catatonia does not necessarily imply schizophrenia, it is also true that catatonic and other persistent psychomotor phenomena comprise an intrinsic symptom dimension of psychotic disorders, with implications for treatment, prognosis, and neurobiological research.

### Kahlbaum and Kraepelin: Contributions to the Concept and Nosology of Catatonia

Every major modern and classical writer acknowledged the ubiquitous nature of motor signs and symptoms in patients with severe mental illness.<sup>1–5</sup> Although Kahlbaum proposed catatonia as a single disorder, he instead described a loosely defined syndrome appearing in a variety of conditions.<sup>1</sup> Berrios<sup>4</sup> aptly remarked that “There is a difference between what Kahlbaum actually described and what he thought he was describing at the time.” Of the 26 patients Kahlbaum included in his

<sup>1</sup>To whom correspondence should be addressed; tel: +852-2607-6027, fax: +852-2647-5321, e-mail: gsungvari@gmail.com

monograph,<sup>1</sup> 11 had “neurological” signs and 9 had epileptic seizures; etiologically, there were 2 cases each of tuberculosis and general paresis, 1 case of peritonitis complicated by delirium and 1 case was too brief to draw any conclusion. A factor analysis of Kahlbaum’s cases clearly delineated a neurological and a “psychotic depression” factor.<sup>4</sup> Although Kahlbaum advocated longitudinal observations, few of his cases were followed and the outcome was far from benign: only 8 of his cases remitted, whereas 8 died or became chronic and in 10 cases no follow-up information was provided.<sup>4</sup>

Kraepelin had a sophisticated view of the psychopathology of catatonia. He did not arbitrarily subsume catatonia under dementia praecox without supporting evidence. Starting in 1891, he systematically followed a large number of patients meticulously recording careful observations.<sup>6</sup> He published the first longitudinal study involving 63 cases of catatonia followed for up to 4 years.<sup>7</sup> Only 24 patients remitted from the index episode and 14 of these relapsed within a short period. Nine of the remaining 10 remitted patients continued to display mild disturbances. Because of its recurring course and poor prognosis in his follow-up study, Kraepelin regarded catatonia as a subtype of dementia praecox in successive editions of his textbook.

It is important to note that Kraepelin considered catatonic symptoms as “secondary accompanying phenomena”<sup>8(pp248/255)</sup> and not fundamental clinical manifestations of dementia praecox. By the eighth edition of his textbook, Kraepelin described 11 clinical forms of dementia praecox, only 1 of which was called catatonia (“Catatonia, excitement, stupor [melancholia attonita]”) though catatonic symptoms appeared in other forms as well.<sup>8</sup> Predominantly, catatonic types formed 19.5% of all dementia praecox cases in his series.<sup>8(p153)</sup> Despite their frequency, he could not distinguish well-circumscribed catatonic syndromes within dementia praecox: “the catatonic symptoms may be present in the morbid picture in all possible grades and groupings”.<sup>8(p254)</sup>

Kraepelin did not simply equate catatonia with dementia praecox. He was fully aware that motor symptoms occur in other psychiatric and medical conditions, emphasized that catatonic symptoms were not sufficient to diagnose dementia praecox, and had only a preliminary place in his classification system: “So far as judgment on the subject is possible today, we may regard the catatonia of Kahlbaum as in the main a form, though peculiar, of dementia praecox. On the other hand, catatonic morbid phenomena are undoubtedly also observed in many quite different morbid processes to a greater or lesser extent, so that its appearance alone does not justify the conclusion that catatonia in the sense just indicated is present”.<sup>8(p132)</sup> However, in no other psychiatric conditions were catatonic symptoms observed “in such extent and multiplicity”<sup>8(p257)</sup> than in dementia praecox. Of the catatonic symptoms, negativism and mannerism were of diagnostic

importance being “more characteristic ... [and] scarcely accompanying any other morbid process in a pronounced form throughout a long period”,<sup>8(p258)</sup> while waxy flexibility and echophenomena were “not rare” in manic-depressive illness nor was stupor combined with cataplexy.<sup>9(pp36,79,106)</sup> It is important to mention here that catatonia in Kraepelin’s sense meant *persisting motor phenomena*; following continuous observation of the patient and based on the opinion of several clinicians, the initial diagnosis was made within 4 weeks of admission in his clinic,<sup>6</sup> with further observations continuously added to refine the diagnosis until the case was closed.<sup>10(pp61–62)</sup>

Addressing the presence of catatonic symptoms in manic-depressive illness, Kraepelin elaborated on the *specific quality* of the catatonic phenomena that distinguish dementia praecox from manic-depressive illness.<sup>8(pp261–270)</sup> Thus, for Kraepelin, the justification for keeping catatonia as part of dementia praecox was its *unique psychopathological pattern and duration*. Motor signs and symptoms in other illnesses including mania and depression similar to those seen in dementia praecox were mentioned without the catatonic adjective as opposed to the “genuine catatonic morbid symptoms” in dementia praecox.<sup>8(p258)</sup> Having examined transient catatonic states in healthy individuals and a variety of psychiatric and neurological conditions, Schneider<sup>11</sup> reached the same conclusion that fleeting motor symptoms in acute psychoses do not justify the catatonic adjective in the diagnosis. A comparison between catatonic and manic excitement observed in 100 patients in each group seemed to support Kraepelin’s view despite some overlap of symptomatology: blocking (29 vs 2), waxy flexibility (15 vs 2), stereotyped speech (29 vs 7), mutism (48 vs 8), and negativism (52 vs 8) predominated in agitated schizophrenia patients.<sup>12</sup> Clearly, the distribution of catatonic symptoms in functional psychoses depends on where the division between schizophrenia and mood disorders is drawn and how catatonia is defined; both decisions are, to a large extent, arbitrary. Broadly defined mania and catatonia results in a high frequency of catatonic symptoms,<sup>13–15</sup> whereas the opposite is expected using a restrictive (Schneiderian) concept of.<sup>16</sup>

For Kraepelin, persistent motor symptoms defined a catatonic subtype of dementia praecox just as enduring negative symptoms define the current concept of deficit syndrome in schizophrenia.<sup>17</sup> The psychopathological aspect of the Kraepelinian legacy has been largely overlooked by modern catatonia research with few exceptions.<sup>18</sup>

### Psychopathological and Diagnostic Issues of Catatonia

In our opinion, the main problem is not the place of catatonia in *DSM* but its lack of conceptual clarity. Few modern writers realize that catatonia has no clear definition.<sup>19,20</sup> Lohr and Wisniewski noted that most

investigators assumed that catatonia was a “coherent, well-defined syndrome ... without ever defining exactly what it was,”<sup>19(p204)</sup> and “catatonia has not been fully defined”.<sup>19(p208)</sup>

Based on the broad methodological principles of “understanding” and “explanation”, Jaspers provided a general psychopathological definition of catatonia that remained the guiding principle in most schools of European psychiatry: “Somewhere between the neurological phenomena, seen as disturbances of the motor apparatus, and the *psychological* phenomena, seen as sequelae of psychic abnormality with the motor apparatus intact, lie the *psychic motor phenomena*, which we register without being able to comprehend them satisfactorily one way or the other.”<sup>21(p179)</sup> For Jaspers, catatonic signs and symptoms constituted the psychic motor phenomena,<sup>21(p179)</sup> whereas the psychological phenomena, such as hysterical or depressive stupor, were “not conceived to be primary motor phenomena but are actions and modes of expressions which have to be understood.”<sup>21(p179)</sup> This is the theoretical viewpoint that essentially restricted catatonia to the schizophrenic psychoses<sup>21(p183)</sup> but acknowledged the presence of a variety of motor symptoms in other psychiatric disorder without calling them catatonic. Similar to Kraepelin, Kleist<sup>22</sup> and the Wernicke-Kleist-Leonhard school of psychiatry regarded only qualitatively abnormal psychomotor phenomena as catatonic.

Modern psychiatry ignores Jaspers’ concept of catatonia but makes no attempt to redefine it in psychopathological terms, which is the most significant stumbling block in modern catatonia research. There is no guiding principle of what makes a motor symptom catatonic, and consequently, the boundaries of catatonia have become unclear. For example, “denudativeness” or “prankishness” is sometimes included in catatonia<sup>19(p205)</sup> and recently priapism<sup>23</sup> and “catatonic coma”<sup>24</sup> were mentioned, whereas, loquaciousness,<sup>1</sup> blocking,<sup>8</sup> or “bizarries”,<sup>25</sup> three classical symptoms have nearly disappeared from its symptomatology. One may ask, for instance, why akathisia—described in 1901 as a motor disorder accompanied by psychological symptoms<sup>26</sup>—is not subsumed under catatonia, at what point psychomotor retardation in depression becomes catatonic, or why “grasp reflex” is part of catatonia but not other signs of frontal lobe dysfunction?<sup>27,28</sup> Similarly, excitement, a core catatonic symptom, has not been systematically examined in modern studies.

There is still no consensus on which signs and symptoms constitute a catatonic syndrome or syndromes.<sup>20</sup> Bleuler questioned the existence of a catatonic syndrome: “I would not insist that these symptoms are intrinsically more related to each other than to other symptoms.”<sup>29(p180)</sup> Lohr and Wisniewski<sup>19(p211)</sup> pointed out that “Because catatonia at the present time is not well-defined as a clinical syndrome, it is questionable whether

all the different clinical descriptions in the many case reports of catatonia represent the same clinical state. For example, many patients have been called catatonic on the basis of mutism and rigidity, and in many cases, it is not clear what the authors considered to be catatonic (as opposed to say, parkinsonian) signs.” Factor and latent class analytic studies suggest that beyond the classical retarded-agitated division, there are further syndromes within the domain of catatonia depending on the type of patients and the number of catatonic symptoms examined.<sup>18,30–33</sup> Preliminary evidence indicates that the symptom profile of catatonia observed in chronic psychotic patients<sup>34–36</sup> appears to be different from acutely emerging mostly stuporous catatonic states and may constitute a separate condition or a group of conditions as proposed by the Wernicke-Kleist-Leonhard school.<sup>37</sup>

Owing to the conceptual confusion, the existing diagnostic systems and catatonia rating scales significantly differ from each other in terms of the time-frame of the examination and the number, composition, and definitions of signs and symptoms that would form the catatonic syndrome(s). *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) (*DSM-IV*)<sup>38</sup> and *International Classification of Diseases, Tenth Revision* (*ICD-10*)<sup>39</sup> list 11 and 9 signs and symptoms, respectively, for catatonia. In modern studies, symptoms assessed for catatonia range from 8 to 40.<sup>14,18,27,28,32,35,36,40–43</sup> The definitions of the same items on different scales are inconsistent even for such basic symptoms as mannerism or rigidity. In addition, the symptom threshold for the diagnosis of catatonia varies from 1<sup>14,39</sup> to any combinations of 2 to 4 symptoms.<sup>15,19,28,36,38,41,42</sup>

Modern rating scales provide a cross-sectional assessment, although catatonic symptoms fluctuate over time such that longer periods of observation are needed to obtain the full picture.<sup>8,29,37</sup> This potential bias in describing catatonic phenomena was demonstrated by a recent study<sup>43</sup>: Significantly more symptoms ( $8.4 \pm 3.3$  vs  $4.1 \pm 1.8$ ) were rated in chronic psychotic patients based on long-term observation as opposed to the standard cross-sectional assessment. A further problem is that all rating scales were validated on acute, mostly akinetic catatonic patients. Consequently, one such scale had to be significantly modified to adjust it to chronic catatonic patients.<sup>44</sup>

While classical texts provide excellent starting points in the current debate on catatonia, eventually modern studies using sophisticated assessment methods are necessary to determine its nosological position. The ideal methodological requirements would be the prospective, independent screening, and evaluation of motor and other psychiatric symptoms with standardized rating instruments in a large sample with mixed diagnoses coupled with neurobiological tests and long-term follow-up. Currently, there are no extensive clinical or follow-up studies



attempting to delimit the clinical boundaries and course of catatonia that meet these criteria.

### Treatment Response and the Heterogeneity of Catatonia

There are consistent clinical reports that benzodiazepines are effective in acute catatonic syndromes, particularly stuporous conditions but no placebo-controlled randomized studies have been published.<sup>45</sup> Due to its favorable pharmacokinetic properties,<sup>46</sup> lorazepam is widely recommended as the drug of choice in catatonia but other benzodiazepines or other agents may also be effective.<sup>46–50</sup> However, the efficacy of lorazepam in treating acute catatonic symptoms in schizophrenia seems to be limited compared with catatonia associated with mood or other disorders.<sup>51,52</sup> According to a recent review, only 20%–30% of patients with catatonic symptoms in the context of schizophrenia respond to benzodiazepines.<sup>45</sup>

Enduring catatonic symptoms in chronic psychoses have received less attention. The only controlled study testing the efficacy of lorazepam in persistent catatonia was a 12-week long randomized placebo-controlled crossover trial involving chronic schizophrenia patients with prominent catatonic symptoms.<sup>53</sup> None of the 16 patients showed noticeable improvement in catatonia on lorazepam. Similarly, in a 5-year open study, benzodiazepines were ineffective in chronic catatonic schizophrenia.<sup>54</sup> The lack of response to lorazepam of catatonia observed in chronic psychotic patients raises again the possibility that acute and chronic catatonic conditions may have different pathophysiology.

Case series and retrospective reviews indicate that acute catatonic syndromes also respond well to electroconvulsive therapy (ECT).<sup>55,56</sup> However, catatonia associated with schizophrenia was less likely to respond than that with mood or medical disorders<sup>57,58</sup> but ECT is still superior to benzodiazepines in these patients.<sup>59,60</sup> The only controlled study involving patients with chronic catatonic schizophrenia that met the methodological criteria for inclusion into the Cochrane analysis compared ECT, nonconvulsive stimulation, and sham ECT.<sup>61</sup> No significant differences between the effects of the 3 methods were found with regard to short-term outcome.

In summary, while benzodiazepines and ECT are often dramatically effective in acute stuporous catatonia as discussed by Fink *et al.*,<sup>1</sup> preliminary results in patients with catatonia associated with chronic psychoses are discouraging and suggest that catatonic symptoms may be heterogeneous in both psychopathology and neurobiology.

### Catatonic Schizophrenia

There is overwhelming evidence from the preantipsychotic era as well as from studies of drug-naïve patients that a variety of psychomotor symptoms are an integral

part of the acute<sup>40,51,62,63</sup> and particularly in the chronic phase of schizophrenia.<sup>34,36,64,65</sup> Preliminary evidence suggests that the symptom profile of catatonia in schizophrenia is different from that of other catatonic disorders,<sup>18</sup> a notion that harks back to Kraepelin and Bleuler.<sup>29(p211)</sup> Limited data also indicate that catatonia in the chronic phase of schizophrenia is phenomenologically different from what is usually observed in an acute episode; chronic patients display more stereotypes, mannerisms, automatic movements and bizarre postures, and less immobility, mutism and vegetative symptoms.<sup>33,36,66</sup> Significant associations have been found in schizophrenia between catatonia and sex, younger age, parkinsonian and negative symptoms, and more severe psychopathology.<sup>36,42,66–69</sup> Interestingly, residual but not the acute motor symptoms were correlated with clinical variables.<sup>42</sup>

Although catatonia was routinely and erroneously equated solely with schizophrenia in the United States, early in the last century, recent evidence is less convincing that patients with catatonia are mostly or disproportionately diagnosed with schizophrenia today. In a review of 11 studies surveying the rates of disorders underlying catatonia, we found a mean of 28% of catatonic patients diagnosed with schizophrenia (range 7%–67%) vs 44% diagnosed with mood disorders (range 28%–71%).<sup>70</sup> In fact, contrary evidence suggests a dramatic decline in the diagnosis of catatonic symptoms among patients with schizophrenia over the last century. Although the recognition of catatonia among psychiatric patients in general has increased, the diagnosis of catatonia attributed to schizophrenia has nearly vanished in the United States. In a recent unpublished analysis using a national database, we found that fewer than 0.4% of patients discharged from hospitals in the United States with schizophrenia were diagnosed with the catatonic subtype (<http://hcupnet.ahrq.gov>), significantly less than the 7%–17% having catatonia in general psychiatric populations.<sup>70</sup> During the 20th century, the percentage of patients with the catatonic subtype of schizophrenia dropped to single digits in the developed world.<sup>71,72</sup> Studies comparing different periods of time at single sites using consistent criteria showed a significant decline in the diagnosis of catatonic schizophrenia ranging from 28.8% to 77.0% since the Kraepelinian era.<sup>71,73–76</sup>

Closer inspection of published data reveals that acute catatonia has been noted only intermittently in the course of schizophrenia, with the rate increasing in proportion to the length of follow-up.<sup>77,78</sup> On the other hand, Stompe *et al.*<sup>71</sup> and Astrup<sup>79</sup> showed that the decline in catatonic schizophrenia is primarily due to the fall-off in diagnosis of catatonia in chronic schizophrenia (mainly “systematic schizophrenia” in the Leonhard system). This finding conflicts with the fact that catatonic symptoms were more frequently observed in patients with chronic schizophrenia in the historical record and are more common among chronically ill populations in

institutional settings and in developing nations.<sup>51,69,80–82</sup> Although numerous reasons have been proposed for the decline in the recognition of catatonic schizophrenia, we favor the hypothesis that catatonic symptoms classically associated with chronic schizophrenia are no longer recognized because of changing diagnostic fashions and the de-emphasis of descriptive psychopathology. The influence of diagnostic bias was demonstrated by Stompe et al,<sup>83</sup> who showed a direct correlation between the number of catatonic signs used in classification systems (57 in Leonhard vs 11 in *DSM-IV*) and the prevalence of catatonic schizophrenia (23.6% vs 9.5%, respectively). Applying *ICD-10, Diagnostic and Statistical Manual of Mental Disorders* (Third Edition Revised), and historical criteria to the same cohort of patients with schizophrenia, Hoffler et al<sup>84</sup> diagnosed the catatonic subtype 3 times more often using traditional classifications.

The influence of catatonia on treatment response and outcome is also rarely considered in treatment trials of schizophrenia, even though rating instruments are available and preclinical data on the second-generation antipsychotic drugs predicted a reduction in liability for inducing or worsening catatonia.<sup>85–87</sup> Catatonic schizophrenia was diagnosed in 7.4% of patients in a trial of clozapine and 5% of patients in a trial of risperidone, but neither treatment response nor worsening of catatonia was reported in either study.<sup>88,89</sup> In a trial by Naber et al,<sup>90</sup> 11.5% of patients were diagnosed with the catatonic subtype of schizophrenia and showed a favorable response to clozapine. Martenyi et al<sup>91</sup> reported an ameliorative effect of olanzapine on catatonic-like symptoms in schizophrenia. In contrast, Girish and Gill<sup>60</sup> showed greater improvement in psychotic and catatonic symptoms from ECT compared with risperidone in a randomized trial of acute catatonic schizophrenia. Evidence from case reports is mixed, with reports of second-generation antipsychotics reducing catatonia, causing catatonia, or precipitating NMS in some patients.<sup>92,93</sup> Several authors published data suggesting that antipsychotic response varies depending on the clinical presentation and duration of symptoms; acute catatonic schizophrenia has a favorable prognosis and response to antipsychotic treatment,<sup>71,76,79,94,95</sup> whereas catatonia correlated with severity, poor treatment response, and chronicity of schizophrenia in other studies.<sup>73,77,95,96</sup>

Similarly, although catatonic symptoms have been invoked as positive predictors of response to ECT in schizophrenia,<sup>97–99</sup> treatment results are limited and mixed. Catatonic symptoms are neglected in modern trials of ECT in mood disorders as well as in schizophrenia.<sup>100,101</sup> However, in a retrospective study, Wells<sup>102</sup> reported preferential response to ECT in patients with catatonic or schizoaffective subtypes of schizophrenia. Dodwell and Goldberg<sup>103</sup> noted “perplexity” as a positive predictive factor. Suzuki et al<sup>59</sup> reported a positive response to ECT in all 11 patients diagnosed with chronic

catatonic schizophrenia unresponsive to medications; Thirhalli et al<sup>104</sup> reported that patients with catatonic schizophrenia responded faster to ECT than other subtypes. However, ECT in combination with clozapine reduced symptoms significantly more in schizoaffective patients than in catatonic or hebephrenic subgroups in a study by Gazdag et al<sup>105</sup> Thus, while psychomotor phenomena are an intrinsic feature of acute and chronic schizophrenia, they are insufficiently recognized in clinical practice and research but may have significant implications for treatment outcome and neurobiological studies.

## Conclusion

In response to a proposal to include catatonia as a separate disorder in *DSM-IV* made 18 years ago,<sup>106</sup> it was pointed out that “a consensus definition of diagnostic criteria for catatonic syndrome with guidelines for determining the threshold for the presence of the symptoms requires input from the growing number of investigators.”<sup>20</sup> This suggestion still rings true today. Due to the lack of conceptual clarity and well-designed prospective follow-up studies, several important issues concerning the psychopathology, diagnosis, treatment, and classification of catatonia remain uncertain such that classifying catatonia in *DSM-V* remains arbitrary.<sup>107</sup>

In our opinion, the most parsimonious options, consistent with current knowledge and historical evidence, would be the following: first, catatonia could be added as a proposed independent entity either in the text of *DSM-V* as proposed by Fink et al<sup>1</sup> or in the appendix among other syndromes for further research; second, to revise and extend the list of psychomotor symptoms defined as catatonic based on unifying and rational psychopathological principles; and third, include revised psychomotor symptoms as a fundamental symptom dimension or criterion for major psychotic and mood disorders. At this juncture, dissociation of catatonia completely from the major psychotic and mood disorders may have unintended consequences; separation may lead to further marginalization of catatonia as a nonspecific syndrome and to continued exclusion from vital research on the significance of psychomotor phenomena as a symptom dimension of psychotic and mood disorders.

## References

1. Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. *Schizophr Res*. July 8, 2009; doi:10.1093/schbul/sbp059.
2. Kahlbaum KL. *Die Katatonie oder das Spannungsirresein*. Berlin, Germany: Hirschwald; 1874.
3. Berrios GE. Stupor revisited. *Compr Psychiatry*. 1981;22:466–478.

4. Berrios GE. *The History of Mental Symptoms*. Cambridge, UK: Cambridge University Press; 1996.
5. Braunig P, Krueger S. History. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. *Catatonia: From Psychopathology to Neurobiology*. Washington, DC: American Psychiatric Press Inc.; 2004:1–14.
6. Berrios GE, Hauser R, Kraepelin. In: Berrios GE, Porter R, eds. *A History of Clinical Psychiatry*. London, UK: The Athlone Press; 1995:280–291.
7. Kraepelin E. Ueber Remissionen bei Katatonie. *Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin*. 1896;52:1126–1127.
8. Kraepelin E. *Dementia Praecox and Paraphrenia*. Edinburgh, UK: E & S Livingstone; 1919.
9. Kraepelin E. *Manic-depressive Insanity and Paranoia*. New York, NY: Arno Press; 1976.
10. Kraepelin E. *Memoirs*. Berlin, Germany: Springer; 1987.
11. Schneider K. Über Wesen und Bedeutung katatonischer Symptome. *Zeitschrift für die gesamte Neurologie und Psychiatrie*. 1914;22:486–505.
12. Bonner CA, Kent GH. Overlapping symptoms in catatonic excitement and manic excitement. *Am J Psychiatry*. 1936;92:1311–1322.
13. Lange J. *Katatonische Erscheinungen im Rahmen manischer Erkrankungen. Monographien aus dem Grenzgebiet der Neurologie und Psychiatrie*. Berlin, Germany: Springer; 1922.
14. Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. *Arch Gen Psychiatry*. 1977;34:1223–1225.
15. Braunig P, Kruger S, Shugar G. Prevalence and clinical significance of catatonic symptoms in mania. *Compr Psychiatry*. 1998;39:35–46.
16. Koehler K, Jacoby C, Guth W. Kurt Schneider's Begriff der zyklischen Manie in Lichte eines forschungs-orientierten Katatonie-Syndromes. *Psychiatr Neurol Med Psychol*. 1981;33:449–457.
17. Carpenter WT, Jr, Arango C, Buchanan RW, Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. *Biol Psychiatry*. 1999;46:352–360.
18. Kruger S, Bagby RM, Hoffer J, Braunig P. Factor analysis of the catatonia rating scale and catatonic symptom distribution across four diagnostic groups. *Compr Psychiatry*. 2003;44:472–482.
19. Lohr JB, Wisniewski AA. *Movement Disorders: A Neuropsychiatric Approach*. New York, NY: Guilford; 1987.
20. Spitzer RL. Commentary. *Integr Psychiatry*. 1991;7:7–9.
21. Jaspers K. *General Psychopathology*. Manchester, UK: Manchester University Press; 1963.
22. Kleist K. *Gehirnpathologie*. Leipzig, Germany: Barth; 1934.
23. Fischel T, Krivoy A, Brenner I, Weizman A. Priapism as an unusual manifestation of catatonia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33:570.
24. Brenner KG, Feutrill J. Comatoid catatonia. *Aust NZ J Psychiatry*. 2000;34:169–170.
25. Bostroem A. Katatone Storungen. In: Bumke O ed. *Handbuch der Geisteskrankheiten*. Vol. 2 Berlin, Germany: Springer; 1928:134–205.
26. Haskovec L. L'akathisia. *Rev Neurol*. 1901;9:1107–1109.
27. Carroll BT, Kirkhart R, Ahuja N, et al. Katatonia: a new conceptual understanding of catatonia and a new rating scale. *Psychiatry*. 2008;5:42–50.
28. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. *Acta Psychiatr Scand*. 1996;93:129–136.
29. Bleuler E. *Dementia Praecox or the Group of Schizophrenias*. New York, NY: International University Press; 1950.
30. Peralta V, Cuesta MJ. Motor features in psychotic disorders. I. Factor structure and clinical correlates. *Schizophr Res*. 2001;47:107–116.
31. Ungvari GS, Goggins W, Leung SK, Gerevich J. Schizophrenia with prominent catatonic features (“catatonic schizophrenia”) II. Factor analysis of the catatonic syndrome. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007;31:462–468.
32. Abrams R, Taylor MA, Stolurow KAC. Catatonia and mania: patterns of cerebral dysfunction. *Biol Psychiatry*. 1979;14:11–117.
33. Ungvari GS, Goggins W, Leung SK, Lee E, Gerevich J. Schizophrenia with prominent catatonic features (“catatonic schizophrenia”) III. Latent class analysis of the catatonic syndrome. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007;31:462–468.
34. Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. *Br J Psychiatry*. 1985;147:221–232.
35. McKenna PJ, Lund CE, Mortimer AM, Biggins CA. Motor, volitional and behavioural disorders in schizophrenia. 2: the ‘conflict of paradigms’ hypothesis. *Br J Psychiatry*. 1991;158:328–336.
36. Ungvari GS, Leung HCM, Cheung HK, Leung T. Schizophrenia with prominent catatonic features (“catatonic schizophrenia”) I. Demographic and clinical correlates in the chronic phase. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005;29:27–38.
37. Leonhard K. *Aufteilung der endogenen Psychosen*. Berlin, Germany: Akademie; 1957;
38. American Psychiatric Association. *DSM-IV: Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Press Inc.; 1994.
39. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders*. Geneva, Switzerland: World Health Organization; 1992.
40. Oulis P, Lykouras L. Prevalence and diagnostic correlates of DSM-IV catatonic features among psychiatric inpatients. *J Nerv Ment Dis*. 1996;184:378–379.
41. Northoff G, Koch A, Wenke J, et al. Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. *Mov Disord*. 1999;14:404–416.
42. Peralta V, Cuesta MJ. Motor features in psychotic disorders. II. Development of diagnostic criteria for catatonia. *Schizophr Res*. 2001;47:117–126.
43. Ungvari GS, Chow LY, Leung HCM, Lau BST. Rating chronic catatonia: discrepancy between cross-sectional and longitudinal assessment. *Revista de Psiquiatria Clinica*. 1999;26:56–61.
44. Wong E, Ungvari GS, Leung SK, Tang WK. Rating catatonia in patients with chronic schizophrenia: Rasch analysis of the Bush-Francis Catatonia Rating Scale. *Int J Methods Psychiatry Res*. 2007;16:161–170.
45. Rosebush PI, Mazurek MF. Pharmacotherapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL eds. *Catatonia: From Psychopathology to Neurobiology*. Washington, DC: American Psychiatric Press Inc.; 2004:141–150.
46. Schmider J, Standhart H, Deuschle M, Drancoli J, Heuser I. A double-blind comparison of lorazepam and oxazepam in



- psychomotor retardation and mutism. *Biol Psychiatry*. 1999;46:437–441.
47. Franz M, Gallhofer B, Kanzow WT. Treatment of catatonia with intravenous biperidene. *Br J Psychiatry*. 1994;164:847–848.
  48. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. *J Neuropsychiatry Clin Neurosci*. 2007;19:406–412.
  49. Kritzinger PR, Jordaan GP. Catatonia: an open prospective series with carbamazepine. *Int J Neuropsychopharmacol*. 2001;4:251–257.
  50. Thomas P, Cottencin O, Rasclé C, Vaiva G, Goudemand M, Bieder J. Catatonia in French psychiatry: implications of the zolpidem challenge tests. *Psychiatric Ann*. 2007;37:45–54.
  51. Lee JW, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. *Ann Clin Psychiatry*. 2000;12:89–96.
  52. Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. *Acta Psychiatr Scand*. 1994;89:285–288.
  53. Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. *Psychopharmacology (Berl)*. 1999;142:393–398.
  54. Beckmann H, Fritze J, Franzek E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics. *Neuropsychobiology*. 1992;26:50–58.
  55. Caroff SN, Ungvari GS, Bhati MT, Datto CJ, O'Reardon JP. Catatonia and prediction of response to electroconvulsive therapy. *Psychiatr Ann*. 2007;37:57–64.
  56. Gazdag G, Mann SC, Ungvari GS, Caroff SN. Clinical evidence for the efficacy of electroconvulsive therapy in the treatment of catatonia and psychoses. In: Swartz CM, ed. *Electroconvulsive and Neuromodulation Therapies*. Cambridge, UK: Cambridge University Press; 2009:124–148.
  57. Pataki J, Zervas IM, Jandorf L. Catatonia in a University in-patient service (1985–1990). *Convulsive Ther*. 1992;8:163–173.
  58. Rohland BM, Carroll BT, Jacoby RG. ECT in the treatment of the catatonic syndrome. *J Affect Disord*. 1993;29:255–261.
  59. Suzuki K, Awata S, Matsuoka H. Short-term effect of ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. *J ECT*. 2003;19:73–80.
  60. Girish K, Gill NS. Electroconvulsive therapy in lorazepam non-responsive catatonia. *Indian J Psychiatry*. 2003;45:21–25.
  61. Miller DH, Clancy J, Cumming E. A comparison between unidirectional current nonconvulsive electrical stimulation given with Reiter's machine, standard alternating current electroshock (Cerletti method), and Penthotal in chronic schizophrenia. *Am J Psychiatry*. 1953;109:617–620.
  62. Caligiuri MP, Lohr JB, Jeste DV. Parkinsonism in neuroleptic-naive schizophrenic patients. *Am J Psychiatry*. 1993;150:1343–1348.
  63. Seethalakshami R, Dhavale S, Suggu K, Dewan M. Catatonic syndrome: importance of detection and treatment with lorazepam. *Ann Clin Psychiatry*. 2008;20:5–8.
  64. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. *Arch Gen Psychiatry*. 1982;39:452–461.
  65. Cernovsky ZZ, Landmark JA, Merskey H, O'Reilly RL. The relationship of catatonia symptoms to symptoms of schizophrenia. *Can J Psychiatry*. 1998;43:1031–1035.
  66. Cohen D, Nicolas JD, Flament MF, et al. Clinical relevance of chronic catatonic schizophrenia in children and adolescents: evidence from a prospective naturalistic study. *Schizophr Res*. 2005;76:301–308.
  67. Peralta V, Cuesta MJ. Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited. *Schizophr Res*. 1999;40:245–253.
  68. Ohaeri JU, Otote DI. Subtypes and factors of schizophrenia in an acutely ill Nigerian sample. *Psychopathology*. 2003;36:181–189.
  69. Kumar M, Ram D, Neeraj B, Sinha P. Prevalence of catatonic signs and symptoms in drug naive/drug free persons suffering from schizophrenia in adult psychiatric clinic. *Indian J Psychiatry*. 2007;49:11.
  70. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Epidemiology. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. *Catatonia: From Psychopathology to Neurobiology*. Washington, DC: American Psychiatric Press Inc.; 2004.
  71. Stompe T, Ortwein-Swoboda G, Ritter K, Schanda H, Friedmann A. Are we witnessing the disappearance of catatonic schizophrenia? *Compr Psychiatry*. 2002;43:167–174.
  72. Hoffler J, Braunig P. Abnahme der Häufigkeit katatonen Schizophrenien im Epochvergleich. In: Braunig P, ed. *Differenzierung katatoner und neuroleptika-induzierter Bewegungsstörungen*. Stuttgart, Germany: G. Thieme; 1995:32–35.
  73. Achte KA. The course of schizophrenia and schizophreniform psychoses. *Acta Psychiatr Neurol Scand Suppl*. 1961;155:1–273.
  74. Templer DI, Veleber DM. The decline of catatonic schizophrenia. *J Orthomol Psychiatry*. 1981;10:156–158.
  75. Morrison JR. Changes in subtype diagnosis of schizophrenia: 1920–1966. *Am J Psychiatry*. 1974;131:674–677.
  76. Hogarty GE, Gross M. Preadmission symptom differences between first admitted schizophrenics in the predrug and postdrug era. *Compr Psychiatry*. 1966;7:134–140.
  77. Guggenheim FG, Babigian HM. Catatonic schizophrenia: epidemiology and clinical course. A 7-year register study of 798 cases. *J Nerv Ment Dis*. 1974;158:291–305.
  78. Hearst ED, Munoz RA, Tuason VB. Catatonia: its diagnostic validity. *Dis Nerv Syst*. 1971;32:453–456.
  79. Astrup C. *The Chronic Schizophrenias*. Oslo, Norway: Universitetsforlaget; 1979.
  80. Carpenter WT, Jr, Bartko JJ, Carpenter CL, Strauss JS. Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. *Arch Gen Psychiatry*. 1976;33:508–516.
  81. Ohaeri JU. Long-term outcome of treated schizophrenia in a Nigerian cohort. Retrospective analysis of 7-year follow-ups. *J Nerv Ment Dis*. 1993;181:514–516.
  82. Chandrasena R. Catatonic schizophrenia: an international comparative study. *Can J Psychiatry*. 1986;31:249–252.
  83. Stompe T, Ritter K, Schanda H. Catatonia as a subtype of schizophrenia. *Psychiatric Ann*. 2007;37:31–36.
  84. Hoffler J, Braunig P, Borner I, Krueger S. Untersuchung zum Einfluss veränderter diagnostischer Kriterien auf die Häufigkeit der Diagnose "katatone Schizophrenie". In:

- Braunig P, ed. *Differenzierung katatoner und neuroleptika-induzierter Bewegungsstörungen*. Stuttgart, Germany: G. Thieme; 1995:43–46.
85. Mortimer AM. Standardized instruments. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. *Catatonia: From Psychopathology to Neurobiology*. Washington, DC: American Psychiatric Press Inc.; 2004:53–64.
86. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353:1209–1223.
87. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. *N Engl J Med*. 1991;324:746–754.
88. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol*. 1993;13:25–40.
89. Juul Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. *Acta Psychiatr Scand*. 1985;71:176–185.
90. Naber D, Holzbach R, Perro C, Hippus H. Clinical management of clozapine patients in relation to efficacy and side effects. *Br J Psychiatry*. 1992;160(suppl 17):54–59.
91. Martenyi F, Metcalfe S, Schausberger B, Dossenbach MR. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. *J Clin Psychiatry*. 2001;62(suppl 2):25–27.
92. Van Den Eede F, Van Hecke J, Van Dalen A, Van den Bossche B, Cosyns P, Sabbe BG. The use of atypical antipsychotics in the treatment of catatonia. *Eur Psychiatry*. 2005;20:422–429.
93. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. *J Clin Psychiatry*. 2002;63(suppl 4):12–19.
94. Morrison JR. Catatonia. Retarded and excited types. *Arch Gen Psychiatry*. 1973;28:39–41.
95. Fish FJ. The influence of the tranquillisers on the Leonhard schizophrenic syndromes. *Encephale*. 1964;53:245–249.
96. Mimica N, Folnegovic-Smalc V, Folnegovic Z. Catatonic schizophrenia in Croatia. *Eur Arch Psychiatry Clin Neurosci*. 2001;251(suppl 1):I17–I20.
97. Fink M, Sackeim HA. Convulsive therapy in schizophrenia? *Schizophr Bull*. 1996;22:27–39.
98. Rudorfer MV, Henry ME, Sackeim HA. Electroconvulsive therapy. In: Tasman A, Kay J, Lieberman J, eds. *Psychiatry*. 2nd ed. New York, NY: John Wiley & Sons; 2003:1865–1901.
99. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. *Cochrane Database Syst Rev*. 2005;(2):CD000076.
100. Chanpattana W, Chakrabhand ML. Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome. *Psychiatry Res*. 2001;105:107–115.
101. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. *J ECT*. 2006;22:59–66.
102. Wells DA. Electroconvulsive treatment for schizophrenia. A ten-year survey in a university hospital psychiatric department. *Compr Psychiatry*. 1973;14:291–298.
103. Dodwell D, Goldberg D. A study of factors associated with response to electroconvulsive therapy in patients with schizophrenic symptoms. *Br J Psychiatry*. 1989;154:635–639.
104. Thirthalli J, Phutane VH, Muralidharan K, et al. Does catatonic schizophrenia improve faster with electroconvulsive therapy than other subtypes of schizophrenia? *World J Biol Psychiatry*. 2009;18:1–6.
105. Gazdag G, Kocsis-Ficzere N, Tolna J. The augmentation of clozapine treatment with electroconvulsive therapy. *Ideggyogy Sz*. 2006;59:261–267.
106. Fink M, Taylor M. Catatonia: a separate category in DSM-IV? *Integr Psychiatry*. 1991;7:2–7.
107. Penland HR, Weder N, Tampi RR. The catatonic dilemma expanded. *Ann Gen Psychiatry*. 2006;7:5–14.